Feb 1 (Reuters) – GlaxoSmithKline PLC (GSK.L) announced a settlement worth $1.25 billion between its ViiV Healthcare and Gilead Sciences Inc (GILD.O) on Tuesday in relation to patent violations by Gilead’s Biktarvy, a medicine to treat human immunodeficiency virus.The companies have agreed on a patent license and Gilead will also pay a 3% royalty on future U.S. sales of Biktarvy, GSK said in a statement.
Novo Nordisk contracts Aspen to produce insulin for Africa | Reuters Novo Nordisk (NOVOb.CO) has contracted...
Germany on Monday launched its autumn vaccination campaign to prevent respiratory infection, promoting an updated COVID-19...
Wendy Nelson stands at Uhuru Peak of Mt. Kilimanjaro, the highest point on the continent of...
Wendy Nelson watched her mother slowly die of Alzheimer’s disease, unable to move or swallow at...
Why Europe’s drug shortages may get worse | Reuter Most European countries reporting shortages of antibiotics...
